ACM
ZNTL icon

Anfield Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Anfield Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$642K Buy
274,516
+31,911
+13% +$82.4K 0.18% 69
2025
Q4 		$328K Buy
242,605
+171,228
+240% +$249K 0.1% 72
2025
Q3 		$108K Hold
71,377
– – 0.03% 122
2025
Q2 		$82.8K Hold
71,377
– – 0.03% 128
2025
Q1 		$113K Sell
71,377
-57,941
-45% -$125K 0.04% 98
2024
Q4 		$392K Buy
129,318
+64,659
+100% +$212K 0.14% 52
2024
Q3 		$238K Buy
64,659
+54,892
+562% +$199K 0.09% 61
2024
Q2 		$39.9K Buy
+9,767
New +$109K 0.02% 121

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Anfield Capital Management's ZNTL Position: Q1 2026 in Review

Anfield Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 13% in Q1 2026, buying an estimated $82.4K and bringing the position to 274,516 shares worth $642K. The position accounts for 0.18% of the portfolio, ranked #69.

Anfield Capital Management first reported a position in ZNTL in Q2 2024 and has held it in 8 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Anfield Capital Management held 274,516 shares of Zentalis Pharmaceuticals worth $642K as of Q1 2026.
  • Anfield Capital Management bought 31,911 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $82.4K.
  • Zentalis Pharmaceuticals made up 0.18% of Anfield Capital Management's portfolio in Q1 2026, its #69 holding.
  • Anfield Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.